Gallbladder problems represent another negative effect of Semaglutide to watch for
Garvey WT, Mechanick JI, Brett EM, et al
Glucagonlikepeptide 1 (GLP-1), an endogenous incretin hormone secreted by intestinal L-cells in response to food intake, and its agonists, have been available for clinical use in Canada since the introduction of liraglutide in 2011
Clinical development opportunity
Like semaglutide, it imitates GLP-1 to prompt the pancreas to produce more insulin, signal the brain to recognize fullness, and slow down digestion by delaying gastric emptying
Semaglutide treatment at a reputable Semaglutide clinic may be the solution you've been looking for